1. Kralev S, Schneider K, Lang S, Süselbeck T, Borggrefe M. Incidence and severity of coronary artery disease in patients with atrial fibrillation undergoing first-time coronary angiography. PLoS One. 2011; 6:e24964. PMID:
21957469.
![crossref](/image/icon/bnr_ref_cross.gif)
2. Authors/Task Force members, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35:2541–2619. PMID:
25173339.
3. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014; 35:3155–3179. PMID:
25154388.
4. Paikin JS, Wright DS, Crowther MA, Mehta SR, Eikelboom JW. Triple antithrombotic therapy in patients with atrial fibrillation and coronary artery stents. Circulation. 2010; 121:2067–2070. PMID:
20458022.
![crossref](/image/icon/bnr_ref_cross.gif)
5. Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010; 170:1433–1441. PMID:
20837828.
![crossref](/image/icon/bnr_ref_cross.gif)
6. Lamberts M, Olesen JB, Ruwald MH, Hansen CM, Karasoy D, Kristensen SL, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation. 2012; 126:1185–1193. PMID:
22869839.
7. Sørensen R, Hansen ML, Abildstrom SZ, Hvelplund A, Andersson C, Jørgensen C, et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet. 2009; 374:1967–1974. PMID:
20006130.
![crossref](/image/icon/bnr_ref_cross.gif)
8. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, et al. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013; 381:1107–1115. PMID:
23415013.
![crossref](/image/icon/bnr_ref_cross.gif)
9. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011; 365:883–891. PMID:
21830957.
![crossref](/image/icon/bnr_ref_cross.gif)
10. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009; 361:1139–1151. PMID:
19717844.
![crossref](/image/icon/bnr_ref_cross.gif)
11. Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016; 375:2423–2434. PMID:
27959713.
![crossref](/image/icon/bnr_ref_cross.gif)
12. Mega JL, Braunwald E, Wiviott SD, Bassand JP, Bhatt DL, Bode C, et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012; 366:9–19. PMID:
22077192.
![crossref](/image/icon/bnr_ref_cross.gif)
13. Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018; 39:1330–1393. PMID:
29562325.
![crossref](/image/icon/bnr_ref_cross.gif)
14. Mehta SR, Bainey KR, Cantor WJ, Lordkipanidzé M, Marquis-Gravel G, Robinson SD, et al. 2018 Canadian Cardiovascular Society/Canadian Association of interventional cardiology focused update of the guidelines for the use of antiplatelet therapy. Can J Cardiol. 2018; 34:214–233. PMID:
29475527.
![crossref](/image/icon/bnr_ref_cross.gif)
15. Angiolillo DJ, Goodman SG, Bhatt DL, Eikelboom JW, Price MJ, Moliterno DJ, et al. Antithrombotic therapy in patients with atrial fibrillation treated with oral anticoagulation undergoing percutaneous coronary intervention. Circulation. 2018; 138:527–536. PMID:
30571525.
![crossref](/image/icon/bnr_ref_cross.gif)
16. Cannon CP, Bhatt DL, Oldgren J, Lip GY, Ellis SG, Kimura T, et al. Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med. 2017; 377:1513–1524. PMID:
28844193.
![crossref](/image/icon/bnr_ref_cross.gif)
17. Piccini JP, Jones WS. Triple therapy for atrial fibrillation after PCI. N Engl J Med. 2017; 377:1580–1582. PMID:
29045197.
![crossref](/image/icon/bnr_ref_cross.gif)
18. Golwala HB, Cannon CP, Steg PG, Doros G, Qamar A, Ellis SG, et al. Safety and efficacy of dual vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of randomized clinical trials. Eur Heart J. 2018; 39:1726–1735a. PMID:
29668889.
![crossref](/image/icon/bnr_ref_cross.gif)
19. Cavallari I, Patti G. Meta-analysis comparing the safety and efficacy of dual versus triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention. Am J Cardiol. 2018; 121:718–724. PMID:
29373105.
![crossref](/image/icon/bnr_ref_cross.gif)
20. Neumann FJ, Sousa-Uva M. ‘Ten commandments’ for the 2018 ESC/EACTS Guidelines on myocardial revascularization. Eur Heart J. 2018; 39:3759. PMID:
30403801.
![crossref](/image/icon/bnr_ref_cross.gif)
21. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S, et al. Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation – the J-ROCKET AF study –. Circ J. 2012; 76:2104–2111. PMID:
22664783.
22. Vranckx P, Lewalter T, Valgimigli M, Tijssen JG, Reimitz PE, Eckardt L, et al. Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: rationale and design of the ENTRUST-AF PCI trial. Am Heart J. 2018; 196:105–112. PMID:
29421002.
![crossref](/image/icon/bnr_ref_cross.gif)
23. Lopes RD, Vora AN, Liaw D, Granger CB, Darius H, Goodman SG, et al. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial. Am Heart J. 2018; 200:17–23. PMID:
29898844.
![crossref](/image/icon/bnr_ref_cross.gif)